Should I Buy PTHS? PTHS 2026 Analysis

Should You Buy Pelthos Therapeutics Inc (PTHS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

25.780

1 Day change

4.41%

52 Week Range

135.000

Analysis Updated At

2026/01/26

Pelthos Therapeutics Inc. (PTHS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong analyst support with high price targets, a promising product pipeline, and a growing revenue base. While technical indicators are neutral to bearish in the short term, the long-term growth potential outweighs these concerns.

Technical Analysis

The technical indicators are neutral to bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 49.93, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 24.842, R1: 26.867, S1: 22.818, R2: 28.118, S2: 21.567.

Options Data

Positive Catalysts

Strong analyst ratings with multiple Buy ratings and high price targets ranging from $50 to $
Successful launch of Zelsuvmi, the first and only at-home treatment for molluscum contagiosum, which is a large, underserved market.
Positive financial growth trends, including a significant increase in net income and EPS in Q3
Gross margin of 59.56%, indicating operational efficiency.

Neutral/Negative Catalysts

Bearish technical indicators in the short term.
Lack of recent news or significant hedge fund/insider activity.
Negative net income of -$16.2M in Q3 2025, though it has improved significantly YoY.

Financial Performance

In Q3 2025, revenue was $7.41M, flat YoY. Net income improved significantly to -$16.24M, up 858.19% YoY. EPS increased to -5.3, up 80.89% YoY. Gross margin remained strong at 59.56%. These metrics indicate improving financial health and operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are highly optimistic about PTHS. Multiple firms, including Lake Street, H.C. Wainwright, Roth Capital, Alliance Global, and Oppenheimer, have initiated or reiterated Buy ratings with price targets ranging from $50 to $75. Analysts highlight the company's strong product pipeline, particularly Zelsuvmi, and its potential to dominate the pediatric dermatology and infectious disease markets.

5 Analyst Rating

Wall Street analysts forecast PTHS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTHS is 59.8 USD with a low forecast of 50 USD and a high forecast of 75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 24.690

Low

Averages

59.8

High

Current: 24.690

Low

Averages

59.8

High

Oppenheimer

Outperform

maintain

$57 -> $60

AI Analysis

2026-01-26

New

Reason

Oppenheimer

Price Target

$57 -> $60

AI Analysis

2026-01-26

New

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Pelthos Therapeutics to $60 from $57 and keeps an Outperform rating on the shares. The firm is updating its ZELSUVMI forecast and Pelthos model following prescription reporting from Metys through the end of December and discussions with management. While the TRx count came in below expectations for Q4, 6,233 actual vs. 8,000, this number still represents growth of 130% from the prior quarter, Oppenheimer notes. Given the inherent uncertainty for product launches into new therapeutic indications, the firm updates its 2026 forecast, but remains comfortable with its long-term view despite the Q4 TRx count miss.

Lake Street

NULL

Buy

initiated

$50

2025-12-03

Reason

Lake Street

Price Target

$50

2025-12-03

initiated

NULL

Buy

Reason

Lake Street initiated coverage of Pelthos Therapeutics with a Buy rating and $50 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PTHS

Unlock Now

PTHS Should I Buy

PTHS Should I Buy

Should You Buy Pelthos Therapeutics Inc (PTHS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch